WO2004013152A3 - Novel targets for lithium therapy - Google Patents

Novel targets for lithium therapy Download PDF

Info

Publication number
WO2004013152A3
WO2004013152A3 PCT/US2003/024675 US0324675W WO2004013152A3 WO 2004013152 A3 WO2004013152 A3 WO 2004013152A3 US 0324675 W US0324675 W US 0324675W WO 2004013152 A3 WO2004013152 A3 WO 2004013152A3
Authority
WO
WIPO (PCT)
Prior art keywords
lithium
methods
compounds
novel targets
identifying
Prior art date
Application number
PCT/US2003/024675
Other languages
French (fr)
Other versions
WO2004013152A2 (en
Inventor
John D York
Bryan David Spiegelberg
Original Assignee
Univ Duke
John D York
Bryan David Spiegelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, John D York, Bryan David Spiegelberg filed Critical Univ Duke
Priority to AU2003265375A priority Critical patent/AU2003265375A1/en
Publication of WO2004013152A2 publication Critical patent/WO2004013152A2/en
Publication of WO2004013152A3 publication Critical patent/WO2004013152A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03007—3'(2'),5'-Bisphosphate nucleotidase (3.1.3.7)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Compounds for use as lithium-like therapeutic agents and methods and reagents for identifying same as well as compounds for treating lithium-induced toxicity and methods and reagents for identifying same. The compounds modulate the activity of enzymes within pathways upon which lithium has been discovered to act. Also disclosed herein are transgenic animals that serve as models of lithium-induced toxicity and methods of using the transgenic animals for identifying compounds that ameliorate lithium toxicity. Furthermore, disclosed herein are methods of modeling target sites for lithium.
PCT/US2003/024675 2002-08-06 2003-08-06 Novel targets for lithium therapy WO2004013152A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003265375A AU2003265375A1 (en) 2002-08-06 2003-08-06 Novel targets for lithium therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40148002P 2002-08-06 2002-08-06
US60/401,480 2002-08-06

Publications (2)

Publication Number Publication Date
WO2004013152A2 WO2004013152A2 (en) 2004-02-12
WO2004013152A3 true WO2004013152A3 (en) 2005-10-20

Family

ID=31495967

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/024675 WO2004013152A2 (en) 2002-08-06 2003-08-06 Novel targets for lithium therapy

Country Status (3)

Country Link
US (1) US20050037450A1 (en)
AU (1) AU2003265375A1 (en)
WO (1) WO2004013152A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1767946A1 (en) * 2005-09-22 2007-03-28 Institut Pasteur Process of screening a molecule as a candidate drug for the treatment of bipolar disorder
RU2014115999A (en) * 2011-09-22 2015-10-27 Универсидад Де Лос Андес METHOD FOR MONITORING, DIAGNOSTIC AND / OR FORECASTING OF ACUTE KIDNEY DAMAGE AT EARLY STAGE
US9827222B2 (en) * 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
CN113046402B (en) * 2020-09-30 2023-04-28 江南大学 Method for synthesizing PAPS (pap) based on construction of bifunctional enzyme

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KOZLOVSKY S.G. ET AL: "3'(2')-Phosphoadenosine 5'-phosphste Phosphatase is reduced in postmortem frontal cortex of bipolar patients.", BIPOLAR DISORDERS., vol. 4, October 2004 (2004-10-01), pages 302 - 306, XP002990534 *
SPIEGELBERG B.D. ET AL: "Cloning and Characterization of a Mammalian Lithium-sensitive Bisphosphate 3'-Nucleotidase Inhibited by Inositol 1,4-Biphosphate.", J.BIOL.CHEM., vol. 274, no. 19, 7 May 1999 (1999-05-07), pages 13619 - 13628, XP002990535 *
YENUSH L. ET AL: "A novel target of lithium therapy.", FEBS LETTERS., vol. 467, no. 2-3, 11 February 2002 (2002-02-11), pages 321 - 325, XP004260976 *

Also Published As

Publication number Publication date
AU2003265375A8 (en) 2004-02-23
AU2003265375A1 (en) 2004-02-23
US20050037450A1 (en) 2005-02-17
WO2004013152A2 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
WO2003083047A3 (en) MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2002099048A3 (en) LIMKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2005034845A8 (en) Compositions and methods for treatment of cancer
WO2006117660A3 (en) Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
EP2085386A3 (en) Pyridinium and quinolinium derivatives as Choline kinase inhibitors
WO2004013152A3 (en) Novel targets for lithium therapy
WO2004092735A3 (en) Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis
AU2001245319A1 (en) Methods of treating diseases with activated protein c
WO2005016287A3 (en) Prkwnks as modifiers of the rac pathway and methods of use
WO2005010148A3 (en) Marks as modifiers of the pten pathway and methods of use
WO2006036613A3 (en) Mracs as modifiers of the rac pathway and methods of use
WO2002081658A3 (en) Transgenic mice containing cacnb4 calcium ion channel gene disruptions
WO2004066948A3 (en) Mapcaxs as modifiers of the apc and axin pathways and methods of use
WO1999050671A3 (en) Toso as a target for drug screening
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2002062204A3 (en) Methods for diagnosing and treating heart disease
WO2005090992A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2004048540A3 (en) Mracs as modifiers of the rac pathway and methods of use
WO2005017123A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2005034882A3 (en) Composition and method to treat solid tumors
WO2003074672A3 (en) Crebpas as modifiers of cell death pathways and methods of use
WO2004072257A3 (en) Dyrks as modifiers of the apc and axin pathways and methods of use
WO2004014301A3 (en) PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE
WO2003028537A3 (en) Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP